Unknown OBSERVATIONAL NCT05287139

QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions. (BRAVE)

Quality of Life of Women With Hormone Receptor-Positive Metastatic Breast Cancer Treated in the First-line Setting: Comparison Between Public and Private Institutions.

Sponsor: Beneficência Portuguesa de São Paulo

Conditions Breast Neoplasm Female Quality of Life

Interventions Quality of Life

Updated 4 times since 2022 Last updated: Mar 10, 2022 Started: Jul 14, 2021 Primary completion: Jul 30, 2022 Completion: Jul 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05287139, this observational or N/A phase trial focuses on Breast Neoplasm Female and Quality of Life and remains ongoing. Sponsored by Beneficência Portuguesa de São Paulo, it has been updated 4 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status

Status: Enrolling By Invitation → Unknown Status
Apr 2022 — Apr 2024 [monthly]

Enrolling By Invitation

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beneficência Portuguesa de São Paulo

Data source: Beneficência Portuguesa de São Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil